Replies to post #485267 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

1/3rd of the participants in the Phase 2b/3 trial were receiving a placebo

1/3rd of the participants in the Phase 2b/3 trial were targeted to receive just 30 mg/day of Anavex’s blarcamesine

1/3rd of the participants in the Phase 2b/3 trial were targeted to receive 50 mg/day of Anavex’s blarcamesine. However, some of these participants were down titrated to 30 mg/day due to inadequate titration (too quick and not using an intermediate 40 mg/day dose prior to the targeted 50 mg/day dose).

Also approximately 20 of all of these participants did not have a natural wild type of sigma-1 receptor.

So, yes some of these patient progressed to mild to moderate Alzheimer’s disease prior to starting the OLE study using a target dose of 50 mg/day or the highest tolerable dose identified during the in adequate titration process.

GOD bless,